摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-苄氧基羰基氨基-哌啶盐酸盐 | 207296-89-7

中文名称
4-苄氧基羰基氨基-哌啶盐酸盐
中文别名
4-(cbz-氨基)哌啶盐酸盐;4-(CBZ-氨基)哌啶盐酸盐;4-(Cbz-氨基)哌啶盐酸盐
英文名称
benzyl piperidin-4-ylcarbamate hydrochloride
英文别名
benzyl N-(4-piperidyl)carbamate hydrochloride;piperidin-4-ylcarbamic acid benzyl ester hydrochloride;benzyl N-piperidin-4-ylcarbamate;hydrochloride
4-苄氧基羰基氨基-哌啶盐酸盐化学式
CAS
207296-89-7
化学式
C13H18N2O2*ClH
mdl
——
分子量
270.759
InChiKey
PRLHASMXVOZART-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    209 - 211°C
  • 溶解度:
    可溶于氯仿(轻微、加热)、DMSO(轻微)、甲醇(轻微)

计算性质

  • 辛醇/水分配系数(LogP):
    2.09
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    50.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:87167d1cd24d0335beb0d91e979bfcbc
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Benzyloxycarbonylamino-piperidine HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Benzyloxycarbonylamino-piperidine HCl
CAS number: 207296-89-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18N2O2.ClH
Molecular weight: 270.8

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    4-苄氧基羰基氨基-哌啶盐酸盐 在 palladium on activated charcoal 氢气 、 sodium hydride 、 sodium carbonate一水合肼N,N'-羰基二咪唑 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 25.0~100.0 ℃ 、413.69 kPa 条件下, 反应 84.0h, 生成 N-[2-(4-amino-1-piperidinyl)ethyl]-1-isopropylindazole-3-carboxamide
    参考文献:
    名称:
    有效的和口服活性的5-HT4受体拮抗剂:吲唑和苯并咪唑酮衍生物的合成及其构效关系。
    摘要:
    合成了一系列的吲哚-3-羧酰胺,吲唑-3-羧酰胺和苯并咪唑啉酮-3-羧酰胺,并评估了对大鼠食道中5-HT4受体的拮抗剂亲和力。与相应的吲哚类似物相比,吲唑和苯并咪唑酮系列中的3-内环戊胺衍生物具有更大的5-HT4受体亲和力。通过在芳香杂环的N-1烷基化进一步提高了5-HT4受体拮抗剂的亲和力。在一系列的1-异丙基吲唑-3-羧酰胺中,用单环哌啶环系统或无环氨基亚烷基链取代双环托烷环系统导致了有效的5-HT4受体拮抗剂。特别地,其中碱性胺被能够形成氢键的基团取代的那些系统显示出增加的5-HT 4受体拮抗剂活性。尽管这些化合物中的一些对其他神经递质受体(特别是5-HT3,α1和5-HT2A受体)表现出高亲和力,但随着胺部分构象柔韧性的提高,对5-HT4受体的选择性也提高了。从这一系列化合物中,我们确定了LY353433(1-(1-甲基乙基)-N- [2- [4-[(三环[3.3.1.1(3,7)]癸-1-基羰基)氨基]
    DOI:
    10.1021/jm970857f
  • 作为产物:
    描述:
    参考文献:
    名称:
    有效的和口服活性的5-HT4受体拮抗剂:吲唑和苯并咪唑酮衍生物的合成及其构效关系。
    摘要:
    合成了一系列的吲哚-3-羧酰胺,吲唑-3-羧酰胺和苯并咪唑啉酮-3-羧酰胺,并评估了对大鼠食道中5-HT4受体的拮抗剂亲和力。与相应的吲哚类似物相比,吲唑和苯并咪唑酮系列中的3-内环戊胺衍生物具有更大的5-HT4受体亲和力。通过在芳香杂环的N-1烷基化进一步提高了5-HT4受体拮抗剂的亲和力。在一系列的1-异丙基吲唑-3-羧酰胺中,用单环哌啶环系统或无环氨基亚烷基链取代双环托烷环系统导致了有效的5-HT4受体拮抗剂。特别地,其中碱性胺被能够形成氢键的基团取代的那些系统显示出增加的5-HT 4受体拮抗剂活性。尽管这些化合物中的一些对其他神经递质受体(特别是5-HT3,α1和5-HT2A受体)表现出高亲和力,但随着胺部分构象柔韧性的提高,对5-HT4受体的选择性也提高了。从这一系列化合物中,我们确定了LY353433(1-(1-甲基乙基)-N- [2- [4-[(三环[3.3.1.1(3,7)]癸-1-基羰基)氨基]
    DOI:
    10.1021/jm970857f
点击查看最新优质反应信息

文献信息

  • [EN] BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES<br/>[FR] DÉRIVÉS DE 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]MÉTHYL}-1H-1,3-BENZODIAZOL-3-IUM SUBSTITUÉS PAR BIS(PENTAHYDROXYHEXYL)AMINO UTILISÉS EN TANT QU'INHIBITEURS D'ENAC POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
    申请人:ENTERPRISE THERAPEUTICS LTD
    公开号:WO2019077340A1
    公开(公告)日:2019-04-25
    The present invention discloses bis(pentahydroxyhexyl)amino substituted 2-[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3- benzodiazol-3-ium derivatives of formula (I) as inhibitors of ENaC and are of use in the treatment of respiratory diseases and conditions, skin conditions or ocular conditions, wherein the respiratory disease or condition is e.g. cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, including non-cystic fibrosis bronchiectasis, and asthma; the skin condition is e.g. psoriasis, atopic dermatitis and ichthyosis; and the ocular condition is e.g. dry eye disease.
    本发明公开了式(I)的双(戊糖基己基)基取代的2-[(3-氨基吡嗪-2-基)甲酰胺基]甲基}-1H-1,3-苯二唑-3-ium衍生物作为ENaC的抑制剂,并用于治疗呼吸道疾病和症状、皮肤病或眼部病症,其中呼吸道疾病或症状例如囊性纤维化、慢性阻塞性肺病(COPD)、慢性支气管炎、肺气肿、支气管扩张症,包括非囊性纤维化支气管扩张症和哮喘;皮肤病例如屑病、特应性皮炎和鱼鳞病;眼部病症例如干眼症。
  • COMPOUNDS
    申请人:Enterprise Therapeutics Limited
    公开号:US20210188855A1
    公开(公告)日:2021-06-24
    Compounds of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respiratory diseases and conditions, skin conditions and ocular conditions.
    通式(I)中R1、R2、R3、R4和X的化合物是上皮通道(ENaC)的抑制剂,可用于治疗或预防呼吸道疾病和状况、皮肤状况和眼部状况。
  • COMPOUND WITH ANTICANCER ACTIVITY
    申请人:KYOWA KIRIN CO., LTD.
    公开号:US20210024540A1
    公开(公告)日:2021-01-28
    A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L 1 and L 2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
    提供具有抗癌活性的化合物,或其药用可接受的盐。所使用的化合物表示为以下式(I)或其药用可接受的盐: (其中,L1和L2相同或不同,每个代表从(A)到(F)式组成的一种式子所代表的基团,S代表从(S1)到(S18)式组成的一种式子所代表的基团)。
  • Multistep Continuous-Flow Synthesis in Medicinal Chemistry: Discovery and Preliminary Structure-Activity Relationships of CCR8 Ligands
    作者:Trine P. Petersen、Sahar Mirsharghi、Pia C. Rummel、Stefanie Thiele、Mette M. Rosenkilde、Andreas Ritzén、Trond Ulven
    DOI:10.1002/chem.201204350
    日期:2013.7.8
    A three‐step continuous‐flow synthesis system and its application to the assembly of a new series of chemokine receptor ligands directly from commercial building blocks is reported. No scavenger columns or solvent switches are necessary to recover the desired test compounds, which were obtained in overall yields of 49–94 %. The system is modular and flexible, and the individual steps of the sequence
    报道了一种三步连续流合成系统及其在直接从商业构件中组装新系列趋化因子受体配体中的应用。无需使用清除柱或溶剂转换即可回收所需的测试化合物,这些化合物的总产率为49-94%。该系统是模块化且灵活的,该序列的各个步骤可以互换使用,并具有相似的结果,从而扩展了化学反应的范围。生物学评估证实了该趋化因子CCR8受体的活性,并提供了该新配体系列的初始结构-活性-关系(SAR)信息,其中最有效的成员显示了全激动剂活性,单位为纳摩尔浓度。据我们所知,
  • アミジン化合物および殺菌剤
    申请人:日本曹達株式会社
    公开号:JP2016222654A
    公开(公告)日:2016-12-28
    【課題】殺菌活性、安全性に優れ、且つ工業的に有利に合成できる新規なアミジン化合物、及び該アミジン化合物を有効成分として含有する殺菌剤又は植物病害防除剤の提供。【解決手段】式〔I〕で表されるアミジン化合物又はその塩。(Yは無置換/置換の二価の環状アミン残基;X及びZは夫々独立に無置換/置換のアルキレン基等;Wは単結合又は−N(R5)−;R5はH、無置換/置換のヘテロシクロ基等;R1〜R3は夫々独立にH、無置換/置換の炭化水素基等;Aはカルボキシアミジンで置換されたアリール基又はヘテロアリール基)【選択図】なし
    提供一种具有优良杀菌活性、安全性和工业合成优势的新型酰胺化合物,以及含有该酰胺化合物作为有效成分的杀菌剂或植物病害防治剂。该酰胺化合物或其盐由式[I]表示。(其中,Y为未取代/取代的二价环状胺基;X和Z分别独立地为未取代/取代的烷基等;W为单键或-N(R5)-;R5为H、未取代/取代的杂环基等;R1至R3分别独立地为H、未取代/取代的烃基等;A为被羧酰胺取代的芳基或杂芳基)【选择图】无
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫